定了！药明生物宣布在石家庄筹建中国北方最大生物药研发生产中心

药明生物宣布筹建石家庄生物药一体化研发生产中心

WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

(*Please scroll down for English news.)

中国北京，2018年5月16日

全球领先的生物制药技术平台公司药明生物（WuXi Biologics, 2269.HK）今日宣布，在河北石家庄高新区筹建世界领先的生物药一体化研发生产中心，旨在为全球生物药开发、临床生产及商业化生产提供一体化解决方案。预计项目一期工程将于2020年投产。

项目签约仪式在北京隆重举行

药明生物石家庄生物药一体化研发生产中心将由工艺开发实验室、产能5,000升的临床样品生产基地（药明生物九厂）和产能48,000升的商业化生产基地（药明生物八厂）组成，其设计及建设将符合美国、欧盟及中国的cGMP标准。此举将使药明生物成为更深、更广、更宽的生物药研发生产赋能平台，助力提升石家庄生物制药产业的能力和地位，为我国药品上市许可持有人制度（MAH）政策提供产能支持，同时服务范围也将辐射全球。

药明生物全球生产副总裁董健先生代表公司签约

“我非常高兴药明生物能筹建中国北方最大的生物药研发生产中心，这将有助于我们借力区域政府支持，吸引更多本地优秀人才，赋能当地合作伙伴更高效地研发生产生物药，同时为全球合作伙伴提供更强大的供应链网络。”药明生物首席执行官陈智胜博士表示，“考虑到药明生物平台上研发的161个项目未来可期的生产需求，我们将基于此次投资，快速高效地加强生产业务规模和能力，将药明生物打造成为全球生物药商业化生产服务领域的领导者。”

关于药明生物

药明生物作为一家香港上市公司，是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务，帮助任何人、任何公司发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。如需更多信息，请访问：www.wuxibiologics.com.cn。

WuXi Biologics to Build an Integrated Biologics Development, Clinical and Commercial Manufacturing Center in Shijiazhuang

BEIJING, China, May 16, 2018

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to build an integrated biologics development, clinical and commercial manufacturing center in the city of Shijiazhuang, capital of Hebei province in northern China.‬

The new state-of-the-art biologics center will include process development labs, clinical manufacturing facility (MFG9) with 5,000 L bioreactor capacity and commercial manufacturing facility (MFG8) with 48,000 L bioreactor capacity which will be built to meet cGMP standards of the United States, the European Union, and China. Besides serving global clients, the new integrated center will also support Marketing Authorization Holder (MAH) system in China and address urgent needs of Chinese partners. Initial phase of the center will be operational in 2020.

“We are very pleased to establish the largest biologics center in northern China, which will enable local companies to more effectively develop and manufacture biologics and in the meantime provide a robust supply chain network for our global clients. This expansion will allow us great access to local talents, markets and government support.” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics. “With this investment and current 161 biologics programs that WuXi Biologics will manufacture, we will quickly and cost effectively expand our manufacturing capacity to meet our partners’ needs and become one of the global CMO leaders.”

 

About WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

注：本信息不构成药明生物的信息披露或投资建议